KaloBios Pharmaceuticals is the subject of a securities class action settlement covering investors who purchased or acquired the company's common stock during a narrow two-week window in November and December 2015. The settlement resolved claims related to that trading period and provided a total aggregate gross recovery of $3,000,000.00 cash plus $254,722.73 in proceeds from the sale of 300,000 shares. The claim deadline for this settlement has passed, but the verified record remains here for reference.